Zhang M, O’Keefe D, Iwamoto M, et al. - Researchers presented the first real‐world evidence of the efficacy of sofosbuvir and daclatasvir (SOF+DCV) over a large patient cohort utilizing a simplified care model in Cambodia. They analyzed 9,158 patients (median age: 57 years; 39.6% male) who underwent treatment with SOF+DCV from September 2016 to June 2019. There was significant simplification of medical standard operational procedures over the study period. The predominant genotype was genotype 6 (53.0%). High treatment efficacy was reported, with 97.2% of patients attaining SVR12, among patients analyzed according to modified intention to treat (n = 8,525). They observed a low occurrence of SAE (0.7%). Over patient sub‐groups and during progressive simplification, the SOF+DCV regimen showed high rates of treatment efficacy and safety.